Abstract
Over the past decade, vulnerability- and psychosis-associated structural and functional brain abnormalities in a population at high clinical risk to develop psychosis were intensively studied. We reviewed the results from studies comparing at-risk mental state (ARMS) individuals with and without subsequent transition to psychosis. Additionally, we introduced a new concept of splitting ARMS population according to the duration of the psychosis risk syndrome and their probability to develop psychosis. Studying the ARMS individuals still vulnerable to psychosis but with lower risk to transit can disclose the possible protective – resilience factors or characteristics. Resilience, understood as ability to recover from change, can be thus applied in the early intervention for high clinical risk for psychosis individuals.
Keywords: At-risk mental state (ARMS), transition, psychosis, resilience, magnetic resonance imaging (MRI), gray matter, abnormal experiences, temporal gyrus, insular volume, clinical psychiatry
Current Pharmaceutical Design
Title: Neuroimaging and Resilience Factors - Staging of the At-risk Mental State?
Volume: 18 Issue: 4
Author(s): Renata Smieskova, Paolo Fusar-Poli, Anita Riecher-Rossler and Stefan Borgwardt
Affiliation:
Keywords: At-risk mental state (ARMS), transition, psychosis, resilience, magnetic resonance imaging (MRI), gray matter, abnormal experiences, temporal gyrus, insular volume, clinical psychiatry
Abstract: Over the past decade, vulnerability- and psychosis-associated structural and functional brain abnormalities in a population at high clinical risk to develop psychosis were intensively studied. We reviewed the results from studies comparing at-risk mental state (ARMS) individuals with and without subsequent transition to psychosis. Additionally, we introduced a new concept of splitting ARMS population according to the duration of the psychosis risk syndrome and their probability to develop psychosis. Studying the ARMS individuals still vulnerable to psychosis but with lower risk to transit can disclose the possible protective – resilience factors or characteristics. Resilience, understood as ability to recover from change, can be thus applied in the early intervention for high clinical risk for psychosis individuals.
Export Options
About this article
Cite this article as:
Smieskova Renata, Fusar-Poli Paolo, Riecher-Rossler Anita and Borgwardt Stefan, Neuroimaging and Resilience Factors - Staging of the At-risk Mental State?, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316046
DOI https://dx.doi.org/10.2174/138161212799316046 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypothalamic and Neuroendocrine Changes in Huntingtons Disease
Current Drug Targets Novel Targets for Apoptosis Modulation: BAG3 Protein and Other Co- Chaperones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression
Current Molecular Medicine Disruption of Circadian Rhythms and Sleep in Critical Illness and its Impact on the Development of Delirium
Current Pharmaceutical Design Imaging the Glutamate System in Humans: Relevance to Drug Discovery for Schizophrenia
Current Pharmaceutical Design Immunologic Modulations to Enhance Post-Stroke Recovery
Current Immunology Reviews (Discontinued) Updates on HCN Channels in the Heart: Function, Dysfunction and Pharmacology
Current Drug Targets 9th International Meeting on Metabotropic Gglutamate Receptors (Taormina, Sicily, October 1-6, 2017).
Current Neuropharmacology Clinical and Therapeutic Challenges when Psychiatric Disorders Occur in Neurological Diseases: A Narrative Review
Current Psychiatry Research and Reviews Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View
Current Neuropharmacology D1 and Functionally Selective Dopamine Agonists as Neuroprotective Agents in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Development of a Non Invasive NGF-Based Therapy for Alzheimers Disease
Current Alzheimer Research (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) Mammalian Nucleoside Transporters
Current Drug Metabolism Adenosine A2A Receptors in Psychopharmacology: Modulators of Behavior, Mood and Cognition
Current Neuropharmacology Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders
Current Pharmacogenomics and Personalized Medicine Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Mitochondrial Alterations and Neuropsychiatric Disorders
Current Medicinal Chemistry ENaC in the Brain - Future Perspectives and Pharmacological Implications
Current Molecular Pharmacology 14-3-3 Protein in CSF Reflects SIV-Mediated Pre-Synaptic Damage
Current HIV Research Thyroid Hormones Crosstalk with Growth Factors: Old Facts and New Hypotheses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)